|
|
Ensuring Value of Patient Submissions to Health Technology Assessment
|
|
|
|
|
|
Below is a summary of a workshop coming up in Toronto and Vancouver, presented by the Canadian Organization for Rare Disorders.
Click here to register.
One-day sessions being held in:
Toronto - Feb 15, 2011 (9:00am - 3:30pm)
Vancouver - Mar 31, 2011 (9:00am - 3:30pm)
The Opportunity: In 2010, the Common Drug Review (CADTH), the Ontario Public Drug Program (CED) and BC PharmaCare (DRC) introduced pathways for patients to submit their opinion about the impact of a drug under review. The new pan-Canadian Oncology Drug Review will also include a patient submission process. The Challenge: How can we ensure the patient submission has appropriate impact on the drug review process? What type of information should be presented? How it be integrated? What are the intended benefits? These are challenges that confront drug review committees in all jurisdictions that provide for patient input. A Way Forward: The purpose of this workshop is to: “co-create the means by which patient submissions to drug reimbursement processes can provide added value, with the ultimate goal of ensuring recommendations for appropriate patient access to drugs.”
Presenters: Panelists/Discussants: Elaine MacPhail, CADTH/CDR Diane McArthur, Ontario PDP/CED (Toronto Session) Mona Sabarwhal, p-CODR Bob Nakagawa, BC Pharmaceutical Services (Vancouver Session) Harlon Davey, ON CED Member Participants: Patient Groups, Patients, HC Professionals, Health Policy Analysts and Economists, Industry Partners, Public
Session Dates and Location: Toronto - Feb 15 (Courtyard by Marriott Downtown Toronto)
Vancouver - Mar 31 (Vancouver Marriott Pinnacle Downtown) Costs:
Patients - Complimentary
Advocare Partners - $45
General Registration - $165 Advocare is grateful to Rx&D for providing an unrestricted education grant to help support this workshop.
Canadian Organization for Rare Disorders |
